IN2015KN00375A - - Google Patents

Info

Publication number
IN2015KN00375A
IN2015KN00375A IN375KON2015A IN2015KN00375A IN 2015KN00375 A IN2015KN00375 A IN 2015KN00375A IN 375KON2015 A IN375KON2015 A IN 375KON2015A IN 2015KN00375 A IN2015KN00375 A IN 2015KN00375A
Authority
IN
India
Prior art keywords
cancer patient
lipoplatin
patient
administered
chemotherapy
Prior art date
Application number
Other languages
English (en)
Inventor
Teni Boulikas
George Stathopoulos
Original Assignee
Teni Boulikas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teni Boulikas filed Critical Teni Boulikas
Publication of IN2015KN00375A publication Critical patent/IN2015KN00375A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IN375KON2015 2012-08-13 2012-08-13 IN2015KN00375A (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/050630 WO2014027996A1 (en) 2012-08-13 2012-08-13 Improved methods for treating cancer with reduced renal toxicity

Publications (1)

Publication Number Publication Date
IN2015KN00375A true IN2015KN00375A (enExample) 2015-07-10

Family

ID=50101360

Family Applications (1)

Application Number Title Priority Date Filing Date
IN375KON2015 IN2015KN00375A (enExample) 2012-08-13 2012-08-13

Country Status (13)

Country Link
US (1) US20150258140A1 (enExample)
EP (1) EP2882420A4 (enExample)
JP (1) JP2015528446A (enExample)
CN (1) CN104736143A (enExample)
AU (1) AU2012387681A1 (enExample)
BR (1) BR112015003111A2 (enExample)
CA (1) CA2882156A1 (enExample)
EA (1) EA201590325A1 (enExample)
IN (1) IN2015KN00375A (enExample)
MA (1) MA37931A1 (enExample)
SG (1) SG11201501146VA (enExample)
WO (1) WO2014027996A1 (enExample)
ZA (1) ZA201501123B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2654484C1 (ru) * 2012-05-11 2018-05-21 Ресет Терапьютикс, Инк. Карбазолсодержащие сульфонамиды в качестве модуляторов криптохрома

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04169532A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体含有リポソーム製剤
JPH04169531A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体を含有するリポソーム製剤
EP0551169A1 (en) * 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
EP0929293B1 (en) * 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
DE19954613A1 (de) * 1999-11-12 2001-05-17 Enthone Omi Deutschland Gmbh Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US20120197060A1 (en) * 2009-06-18 2012-08-02 University Of Utah Research Foundation Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology

Also Published As

Publication number Publication date
BR112015003111A2 (pt) 2017-10-10
SG11201501146VA (en) 2015-05-28
CN104736143A (zh) 2015-06-24
JP2015528446A (ja) 2015-09-28
WO2014027996A1 (en) 2014-02-20
MA37931A1 (fr) 2016-07-29
EP2882420A1 (en) 2015-06-17
EP2882420A4 (en) 2016-06-01
ZA201501123B (en) 2020-02-26
US20150258140A1 (en) 2015-09-17
CA2882156A1 (en) 2014-02-20
EA201590325A1 (ru) 2015-09-30
AU2012387681A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
MY196418A (en) Therapeutically Active Compounds and Their Methods of use
HK1221148A1 (zh) 包含tor激酶抑制剂和imid化合物的联合疗法用於治疗癌症
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
MD4643B1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
MY185206A (en) Therapeutically active compounds and their methods of use
PH12016502354A1 (en) Pharmaceutical composition
NZ702469A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
WO2011100769A3 (en) Kinase modulators for the treatment of cancer
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
IN2015KN00375A (enExample)
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
PH12015500306A1 (en) Arry-520 for use in treating cancer in a patient with low aag
UA66112U (ru) Способ лечения злокачественных новообразований головного мозга
RU2012115039A (ru) Способ лечения хронического эндометрита
UA69222U (ru) Способ рефлексотерапии больных с отдаленными последствиями черепно-мозговой травмы
UA88769U (uk) Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності
UA75641U (uk) Спосіб комплексного лікування хворих з набряковими формами раку грудної залози